Literature DB >> 11675357

Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria.

O Cuvillier1, T Levade.   

Abstract

Sphingosine 1-phosphate (S-1P) has been implicated as a second messenger preventing apoptosis by counteracting activation of executioner caspases. Here it is reported that S-1P prevents apoptosis and executioner caspase-3 activation by inhibiting the translocation of cytochrome c and Smac/DIABLO from mitochondria to the cytosol induced by anti-Fas, tumor necrosis factor-alpha (TNF-alpha), serum deprivation, and cell-permeable ceramides in the human acute leukemia Jurkat, U937, and HL-60 cell lines. Furthermore, the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate, which stimulates sphingosine kinase, the enzyme responsible for S-1P production, also inhibits cytochrome c and Smac/DIABLO release. In contrast, dimethylsphingosine (DMS), a specific inhibitor of sphingosine kinase, sensitizes cells to cytochrome c and Smac/DIABLO release triggered by anti-Fas, TNF-alpha, serum deprivation, or ceramide. DMS-induced mitochondrial apoptogenic factor leakage can likewise be overcome by S-1P cotreatment. Hence, S-1P, likely generated through a protein kinase C- mediated activation of sphingosine kinase, inhibits the apoptotic cascade upstream of the release of the mitochondrial apoptogenic factors, cytochrome c, and Smac/DIABLO in human acute leukemia cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11675357     DOI: 10.1182/blood.v98.9.2828

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

Review 1.  Sphingosine kinase regulation and cardioprotection.

Authors:  Joel S Karliner
Journal:  Cardiovasc Res       Date:  2008-11-18       Impact factor: 10.787

2.  Hair Cell Loss Induced by Sphingosine and a Sphingosine Kinase Inhibitor in the Rat Cochlea.

Authors:  Kohsuke Tani; Keiji Tabuchi; Akira Hara
Journal:  Neurotox Res       Date:  2016-01       Impact factor: 3.911

Review 3.  Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.

Authors:  Kenneth C Loh; Dianna Baldwin; Julie D Saba
Journal:  Anticancer Agents Med Chem       Date:  2011-11       Impact factor: 2.505

Review 4.  Cancer treatment strategies targeting sphingolipid metabolism.

Authors:  Babak Oskouian; Julie D Saba
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

5.  Sphingosine kinase-1 is cleaved by cathepsin B in vitro: identification of the initial cleavage sites for the protease.

Authors:  Tarek A Taha; Mazen El-Alwani; Yusuf A Hannun; Lina M Obeid
Journal:  FEBS Lett       Date:  2006-10-12       Impact factor: 4.124

Review 6.  Targeting sphingosine-1-phosphate in hematologic malignancies.

Authors:  Christina E Stevenson; Kazuaki Takabe; Masayuki Nagahashi; Sheldon Milstien; Sarah Spiegel
Journal:  Anticancer Agents Med Chem       Date:  2011-11       Impact factor: 2.505

7.  S1P: the elixir of life for naive T cells.

Authors:  Michaël Pérès; Anne Montfort; Nathalie Andrieu-Abadie; Céline Colacios; Bruno Ségui
Journal:  Cell Mol Immunol       Date:  2017-10-30       Impact factor: 11.530

8.  Diablo: A Double-Edged Sword in Cancer?

Authors:  Jack L Arbiser
Journal:  Mol Ther       Date:  2018-02-20       Impact factor: 11.454

Review 9.  Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.

Authors:  C Evangelisti; C Evangelisti; F Buontempo; A Lonetti; E Orsini; F Chiarini; J T Barata; S Pyne; N J Pyne; A M Martelli
Journal:  Leukemia       Date:  2016-07-27       Impact factor: 11.528

10.  Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.

Authors:  Audrey Dayon; Leyre Brizuela; Claire Martin; Catherine Mazerolles; Nelly Pirot; Nicolas Doumerc; Leonor Nogueira; Muriel Golzio; Justin Teissié; Guy Serre; Pascal Rischmann; Bernard Malavaud; Olivier Cuvillier
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.